drugset / Trial / NCT00460031

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00460031

Phase 2 Completed 34 enrolled Case Comprehensive Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Giving ketoconazole and hydrocortisone together with lenalidomide may be an effective treatment for prostate cancer. PURPOSE: This phase II trial is studying how well giving ketoconazole and hydrocortisone together with lenalidomide works in treating patients with prostate cancer that did not respond to hormone therapy.

Timeline

Start
2006-09-01
Primary completion
2010-08-31
Completion
2010-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Hydrocortisone Other / unclassified 10 mg Oral
Background Hydrocortisone Other / unclassified 20 mg Oral

Indications